eXoZymes (EXOZ) Competitors $9.98 +0.03 (+0.30%) As of 07/25/2025 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. ADCT, OLMA, BNTC, HRTX, ALDX, VOR, AVIR, CRDF, SGMT, and OCGNShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include ADC Therapeutics (ADCT), Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Aldeyra Therapeutics (ALDX), Vor Biopharma (VOR), Atea Pharmaceuticals (AVIR), Cardiff Oncology (CRDF), Sagimet Biosciences (SGMT), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors ADC Therapeutics Olema Pharmaceuticals Benitec Biopharma Heron Therapeutics Aldeyra Therapeutics Vor Biopharma Atea Pharmaceuticals Cardiff Oncology Sagimet Biosciences Ocugen ADC Therapeutics (NYSE:ADCT) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Which has preferable valuation and earnings, ADCT or EXOZ? eXoZymes has lower revenue, but higher earnings than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$75.82M4.30-$157.85M-$1.45-2.27eXoZymes$70K1,193.32-$5.86MN/AN/A Is ADCT or EXOZ more profitable? eXoZymes has a net margin of 0.00% compared to ADC Therapeutics' net margin of -197.64%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics-197.64% N/A -45.57% eXoZymes N/A N/A N/A Do insiders & institutionals believe in ADCT or EXOZ? 41.1% of ADC Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate ADCT or EXOZ? ADC Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 135.92%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ADC Therapeutics is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ADCT or EXOZ? In the previous week, eXoZymes had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for ADC Therapeutics. eXoZymes' average media sentiment score of 0.93 beat ADC Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media. Company Overall Sentiment ADC Therapeutics Neutral eXoZymes Positive SummaryeXoZymes beats ADC Therapeutics on 7 of the 12 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.26M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E RatioN/A21.1828.1020.05Price / Sales1,193.32286.17429.0189.19Price / CashN/A42.7636.2258.56Price / Book7.988.378.665.87Net Income-$5.86M-$55.19M$3.25B$258.55M7 Day Performance7.89%5.88%4.22%3.73%1 Month Performance2.57%17.33%10.51%11.75%1 Year PerformanceN/A4.42%34.40%18.03% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$9.98+0.3%N/AN/A$83.26M$70K0.0029Gap UpADCTADC Therapeutics1.2406 of 5 stars$3.12+2.5%$7.75+148.8%-14.0%$308.94M$75.82M-2.15310OLMAOlema Pharmaceuticals2.4168 of 5 stars$4.51-1.1%$24.50+443.2%-67.9%$308.58MN/A-2.2470Positive NewsBNTCBenitec Biopharma1.7723 of 5 stars$11.74-0.1%$23.83+103.0%+22.5%$308.18M$80K-7.7720High Trading VolumeHRTXHeron Therapeutics3.8111 of 5 stars$2.00-1.0%$5.00+150.0%-38.4%$305.13M$148.52M-33.33300Positive NewsALDXAldeyra Therapeutics2.5136 of 5 stars$5.03-2.5%$9.50+88.9%+26.4%$301.28MN/A-5.1910Positive NewsUpcoming EarningsHigh Trading VolumeVORVor Biopharma3.8809 of 5 stars$2.38+12.3%$5.63+136.5%+131.2%$297.41MN/A-1.44140High Trading VolumeAVIRAtea Pharmaceuticals2.619 of 5 stars$3.46-0.9%$6.00+73.4%+0.0%$296.10MN/A-2.1070News CoveragePositive NewsCRDFCardiff Oncology1.3795 of 5 stars$4.45+0.7%$11.70+162.9%+67.9%$296.06M$680K-4.8420Positive NewsSGMTSagimet Biosciences2.6844 of 5 stars$9.55-0.1%$26.60+178.5%+201.2%$292.90M$2M-5.438News CoverageAnalyst ForecastInsider TradeOCGNOcugen1.2336 of 5 stars$1.00-3.8%$6.00+500.0%-33.1%$292.03M$4.05M-5.2680Positive News Related Companies and Tools Related Companies ADC Therapeutics Competitors Olema Pharmaceuticals Competitors Benitec Biopharma Competitors Heron Therapeutics Competitors Aldeyra Therapeutics Competitors Vor Biopharma Competitors Atea Pharmaceuticals Competitors Cardiff Oncology Competitors Sagimet Biosciences Competitors Ocugen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXOZ Stock Alerts